Cereno and Zaplox Report Q2 2025 Financial Results Amidst Ongoing Losses
Cereno Scientific and Zaplox announce operational losses for Q2 2025, with changes in revenue and efforts to improve financial health.
Key Points
- • Cereno posts a loss of 16.3 million SEK, slightly improved from 19.6 million SEK previously.
- • Zaplox records a reduced loss of 4.2 million SEK, down from 4.6 million SEK last year.
- • Recurring subscription revenue for Zaplox increases by 7%, with stable gross margin at 91%.
- • Companies are implementing strategies to improve financial performance amid challenging market conditions.
In their recently released financial reports for the second quarter of 2025, both Cereno Scientific and Zaplox have continued to face operational losses, albeit with some improvements in their financial performance.
Cereno Scientific, which focuses on medical research, reported a loss of 16.3 million SEK this quarter, signaling a slight recovery from the previous quarter's loss of 19.6 million SEK. The company continues to grapple with financial challenges as it operates in a competitive biotechnology landscape, emphasizing the difficult journey ahead in achieving profitability.
On the other hand, Zaplox, a provider of digital solutions for the hospitality sector, reported a reduced loss of 4.2 million SEK, down from 4.6 million SEK in Q2 2024. Their net revenue saw a minor dip to 5.0 million SEK from 5.1 million SEK year-on-year. In a positive note, recurring subscription revenue increased by 7% and the company maintained a strong gross margin of 91%. Moreover, improvements in cash flow from operating activities were also evident, moving from -4.0 million SEK to -2.3 million SEK. Despite a significant drop in liquid assets from 11.9 million SEK to 3.5 million SEK, Interim CEO Otto Wetterlin noted efforts are underway to optimize the cost structure, aiming for positive cash flow by the end of 2025.